Classification of Pharmaceuticals: Biologics vs. Conventional Medicines

Diagram showing Classification of Drugs by Origin
Share


Diagram showing Classification of Drugs by Origin

Figure 1. Hierarchical Classification of Drugs

Introduction

Medicines can be separated into two broad groups. The first is ‘Synthetic Medicines‘. As the name suggests they are created through supervised chemical synthesis. The associated chemical reactions are relatively simple and often sequential. The final active substances produced are small molecules with relatively simple chemical structures, an example being aspirin (Figure 2).


Natural Products
Aspirin Molecule

Figure 2. Aspirin Molecule (Black balls represents Carbon atoms)

By contrast natural products are derived from comparatively complex starting materials sourced from the ‘Natural Environment‘. More specifically, they are derived from living organisms or their by-products. Traditionally, these living organisms have been plants from which relatively complex compounds have been extracted, purified and used as medicines. In some cases these compounds have been chemically-modified giving rise to ‘Semi-synthetic‘ drugs. An example from this group is paclitaxel which is derived from bark extracts of the Pacific Yew Tree (Taxus brevifolia) (Craig & Stitzel, 1994: 694) and used to treat various cancers.

Share this Post

Recombinant Products

The most structurally complex group of pharmaceuticals is a sub-group of ‘Natural Products‘ that are termed ‘Recombinant Products‘. They are derived from ‘Natural Sources‘ but the genetic material (DNA) coding for these products in living organisms is deliberately altered to yield a product with specific characteristics.

Space-filling diagram of Monoclonal Antibody

Figure 3. Space-filling diagram of Monoclonal Antibody (Black balls represent carbon atoms)

This is commonly referred to as “Genetic Engineering (GE)” and results in proteins which typically are not found in nature. Invariably the process requires ‘combining‘ genetic material from different species so the term ‘Recombinant‘ is included in the name of the final product to reflect this. One such example is, ‘Recombinant Interferon alpha-2b‘ (Rieger, 1995: 71).

A major distinction between conventional ‘small-molecule‘ pharmaceuticals and this newer class of recombinant proteins is molecular weight and structural complexity. As suggested by Figure 2, Aspirin, an example of a conventional pharmaceutical product is relatively small and structurally simple. This contrasts significantly with the diagram of a ‘monoclonal antibody (mAb)‘ in Figure 3 which falls in the category of large, highly complex ‘recombinant proteins‘. The scale in both diagrams is not equal but in both cases the black / dark grey balls represent Carbon atoms. With a little imagination, it becomes clear that were they represented to equal scale, the mAb would be many hundreds and possibly thousands of times larger  and more complex than aspirin. This single difference has many implications for use and storage of recombinant proteins and many of these implications will be explored in greater detail in future posts.



[adsense728x90DefaultLBToAppearHere]
References
  1. Craig,C.R. & Stitzel, R.E. (1994) Modern Pharmacology. 4th ed. Boston: Little, Brown and Company.
  2. Rieger, P.T. (1995) Biotherapy: A Comprehensive Overview. 1st ed. London: Jones and Bartlett Publishers International.


About the Author
Stewart Dougan

Stewart Dougan

Facebook Twitter Google+

Stewart has 15-plus years in the pharmaceutical industry. With a passion for biopharmaceuticals, he has completed research into how they are perceived by Health Care Professionals as well as the obstacles hindering development of a biopharmaceutical sector in Jamaica. He holds a B.Sc. in Biochemistry, an M.Sc. in Applied Pharmacology and an MBA.

Share

14 Comments on “Classification of Pharmaceuticals: Biologics vs. Conventional Medicines”

  1. Hello, Neat post. There is a problem along with your web site in web explorer, might check this¡K IE still is the marketplace leader and a huge component to folks will leave out your fantastic writing due to this problem.

  2. I seriously enjoy what you post right here. Extremely insightful and intelligent. One concern though. I’m running Firefox with Debian and parts of your current page layout pieces are a little wonky. I realize it’s not a normal set up. But it’s something to hold in the mind. I wish that it will probably help and keep the finest quality writing.

  3. Thanks for a marvelous posting! I truly enjoyed reading it, you can be a great author.I will be sure to bookmark your blog and will come back later on. I want to encourage that you continue your great work, have a nice day!

Leave a Reply